Evidence map›Paper›PMID 37530526›Full record

Observational studyJournal of surgical oncology2023

Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.

Courtney M Lattimore, William J Kane, Shalini Subbarao, Corinne Venitti, Christopher L Cramer, Lena M Turkheimer, Todd W Bauer, Florence E Turrentine, Victor M Zaydfudim

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Courtney M LattimoreDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
William J KaneDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Shalini SubbaraoDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Corinne VenittiDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Christopher L CramerDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Lena M TurkheimerDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Todd W BauerDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Florence E TurrentineDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
Victor M ZaydfudimDivision of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.ORCID http://orcid.org/0000-0003-4572-7038
University of Virginia · US

Funding

Postdoctoral Training Grant for MDs in Surgical Oncology ResearchT32CA163177 · NCI · UNIVERSITY OF VIRGINIA · PI Craig Lee Slingluff, Allan Tsung · 2011 to 2026
$4.6M
NCI NIH HHS L30 CA220861NCI NIH HHS T32 CA163177
6 · The paper itself

Abstract

introductionLong-term data evaluating clinical outcomes in patients with branch-duct Intraductal papillary mucinous neoplasms (BD-IPMN) without high-risk stigmata (HRS) or worrisome features (WF) remain limited.

methodsThis observational cohort study included all patients diagnosed with BD-IPMN without HRS or WF between 2003 and 2019 who were enrolled in a prospective surveillance program. Time-to-progression analysis was performed using a cumulative incidence function plot and survival analysis was conducted using Kaplan-Meier.

resultsThe median follow-up time for the 267 patient cohort was 44.5 months (interquartile range [IQR]: 24.1-72.2). Radiographic cyst growth was observed in 123 (46.1%) patients; 65 (24.3%) patients progressed to WF/HRS. Twenty-six (9.7%) patients were selected for resection during surveillance: 21 (80.8%) WF, 4 (15.4%) HRS; 1 (3.9%) transformed to mixed-duct. Of all the patients who underwent resection, 5 (19.2%) had adenocarcinoma, and 1 (3.8%) had carcinoma-in-situ. The probability of any radiographic progression was 21.3% (5-year) and 51.3% (10-year). For the entire cohort, there was 1.1% mortality secondary to pancreatic adenocarcinoma and 8.2% all-cause mortality. The 5-year overall survival rate was 91.5%, and at 10 years, 81.5%.

conclusionApproximately one in four patients with nonworrisome BD-IPMN have progression to WF/HRS stigmata during surveillance. However, the risk of malignant transformation remains low. Surveillance strategy remains prudent in this patient population.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalNeoplasms, Cystic, Mucinous, and SerousPancreatic Intraductal NeoplasmsPancreatic NeoplasmsHumansPancreatic DuctsProspective StudiesRetrospective Studiesbranch-ductIPMNpancreatic neoplasmpancreatic surgerysurveillance

Identifiers

PMID37530526
PMCPMC10592219
OpenAlexW4385477058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.